Digest Réseau Comment ça marche
Réseau
/
Sociétés
Ot
Non vérifié

Otsuka Pharmaceutical Co., Ltd.

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

23 communiqués de presse

Voir tous les communiqués de presse
22/09/2026
Industrie
Santé
Hygiène alimentaire
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0
19/09/2026
Science
Biotechnologie
Industrie pharmaceutique
Santé
Psychiatrie
Médecine - Divers
Industrie
Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0
03/08/2026
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0
25/07/2026
Biotechnologie
Santé Publique
Hygiène alimentaire
Santé
Industrie pharmaceutique
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0
01/07/2026
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé Publique
Santé
Hygiène alimentaire
Médecine - Divers
Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0
25/06/2026
Industrie
Psychiatrie
Hygiène alimentaire
Santé
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0
12/06/2026
Marché financier
Biotechnologie
Santé Publique
Psychiatrie
Santé
Industrie pharmaceutique
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0
04/06/2026
Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0
28/05/2026
Science
Biotechnologie
Industrie pharmaceutique
Santé
Hygiène alimentaire
Médecine - Divers
Événements
Industrie
Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0
25/03/2026
Événements
Industrie
Santé Publique
Hygiène alimentaire
Santé
Industrie pharmaceutique
Médecine - Divers
Otsuka Showcases New Efficacy and Safety Data of VOYXACT® (sibeprenlimab-szsi) in Patients with IgA Nephropathy (IgAN) at the 2026 ISN World Congress of Nephrology Highlighting the Impact of APRIL Inhibition
Source
Otsuka Pharmaceutical Co., Ltd.
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0